Genesis MedTech’s Transfemoral J-Valve Approved in China to Treat Aortic Regurgitation

September 22, 2025—Singapore-based Genesis MedTech announced that its structural heart subsidiary, Suzhou Jiecheng, has received regulatory approval from China’s National Medical Products Administration for the J-Valve transfemoral (TF) transcatheter aortic valve replacement (TAVR) system for the treatment of aortic regurgitation.

The company advised that 12-month follow-up results on the J-Valve TF device showed a 3.2% rate for all-cause mortality; 94.5% freedom from third-degree atrioventricular block; and improvements in cardiac function and hemodynamic performance. The findings were presented at EuroPCR 2024 by Professor Wei Lai, MD, of Zhongshan Hospital in Shanghai, China.

According to Genesis MedTech, the minimally invasive approach of the J-Valve TF—compared to surgery—reduces surgical trauma and procedural risk while shortening procedure time, with most patients walking the day after treatment. The device’s anchoring design enhances safety by ensuring secure valve placement, protecting coronary flow, and reducing the risk of complications such as paravalvular leak and conduction block.

In August 2024, Genesis MedTech announced it had sold JC Medical, Inc. to Edwards Lifesciences, including the intellectual property and commercial rights of the J-Valve TAVR system. However, Genesis MedTech maintained the exclusive right to develop, manufacture, and commercialize the J-Valve system in Greater China.